Discover
ZURA
Zura Bio Limited
5.09
1 x 3.82
1 x 6.59
bid
ask
+
0.08
1.70%
12:13 PM
timesize
| Ytd | -2.86% | |
| 1y | 354.46% |
5.02
day range
5.39
1.08
52 week range
7.44
| Open | 5.09 | Prev Close | 5.00 | Low | 5.02 | High | 5.39 | Mkt Cap | 482.94M |
| Vol | 371.45K | Avg Vol | 1.03M | EPS | -1.09 | P/E | N/A | Forward P/E | -3.22 |
| Beta | 0.14 | Short Ratio | 14.48 | Inst. Own | 58.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 4.51 | 200-d Avg | 4.75 | 1yr Est | 14.29 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.14 | -0.26 | -0.12 | -85.71% |
| 2024-08-13 | 2024-06 | -0.13 | -0.17 | -0.04 | -30.77% |
| 2024-08-13 | 2024-06 | -0.13 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.23 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.23 | -0.02 | 0.21 | 91.30% |
| 2024-03-26 | 2023-12 | -0.25 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-11-18 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
| 2024-11-08 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-11-04 | Leerink Partners | Upgrade | Outperform | |
| 2024-10-21 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
Profile
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-05-17 | CABELL CHRISTOPHER H | Officer | 162.06K | Stock Award(Grant) |
| 2023-05-17 | DAVIS KIMBERLY ANN | Officer | 492.38K | Stock Award(Grant) |
| 2024-04-21 | HOWELL MICHAEL | Officer | 0.00 | Stock Award(Grant) |
| 2024-04-21 | MUNSHI AMIT D | Director | 777.38K | Stock Award(Grant) |
| 2024-04-21 | NISTALA KIRAN | Officer | 3.20K | Stock Award(Grant) |
| 2024-05-16 | PLOOS VAN AMSTEL ARNOUT | Director | 100.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Suvretta Capital Management, LLC | 4.86M | 11.57M | 7.44% |
| 2024-09-29 | Adar1 Capital Management, LLC | 3.77M | 8.97M | 5.77% |
| 2024-09-29 | Deep Track Capital, Lp | 3.28M | 7.82M | 5.03% |
| 2024-09-29 | Great Point Partners LLC | 3.26M | 7.77M | 5.00% |
| 2024-09-29 | RA Capital Management, L.P. | 3.22M | 7.66M | 4.93% |
| 2024-09-29 | Braidwell LP | 2.47M | 5.89M | 3.79% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | iShares Russell 2000 ETF | 1.01M | 2.40M | 1.54% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 479.14K | 1.14M | 0.73% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 408.10K | 971.28K | 0.63% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 203.56K | 484.47K | 0.31% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 205.18K | 488.33K | 0.31% |
| 2024-08-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 132.54K | 315.44K | 0.20% |